FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial.
作者信息
Urooj Wajiha, Ahmed Bisma, Shahzad Yumna, Siddiqui Amal, Un Nisa Mughal Zaib, Abbasher Hussien Mohamed Ahmed Khabab
机构信息
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
出版信息
Ann Med Surg (Lond). 2024 Sep 10;86(10):5685-5687. doi: 10.1097/MS9.0000000000002564. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial.美国食品药品监督管理局批准纳利妥昔单抗用于转移性胰腺腺癌：一篇社论
Ann Med Surg (Lond). 2024 Sep 10;86(10):5685-5687. doi: 10.1097/MS9.0000000000002564. eCollection 2024 Oct.
2
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌（NAPOLI 3）：一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
3
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.从美国视角看，纳立妥昔单抗对比纳米白蛋白结合型紫杉醇与吉西他滨方案一线治疗转移性胰腺导管腺癌的经济学评估
Cost Eff Resour Alloc. 2024 Sep 18;22(1):70. doi: 10.1186/s12962-024-00578-5.
4
[NALIRIFOX in first-line therapy for metastatic pancreatic adenocarcinoma].[纳立妥用于转移性胰腺腺癌的一线治疗]
Bull Cancer. 2024 Nov;111(11):999-1000. doi: 10.1016/j.bulcan.2024.06.007. Epub 2024 Sep 10.
5
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.一线治疗胰腺导管腺癌的脂质体伊立替康联合奥沙利铂、5-氟尿嘧啶和亚叶酸（NALIRIFOX）：一项 I/II 期研究。
Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4.
6
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.可切除胰腺导管腺癌患者围手术期 NALIRIFOX：开放性、多中心、Ⅱ期 nITRO 试验。
Eur J Cancer. 2024 Jan;196:113430. doi: 10.1016/j.ejca.2023.113430. Epub 2023 Nov 11.
7
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?用于转移性胰腺腺癌的纳立妥昔单抗：希望还是炒作？
Nat Rev Clin Oncol. 2024 Aug;21(8):567-568. doi: 10.1038/s41571-024-00896-w.
8
Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?治疗转移性胰腺导管腺癌：NALIRIFOX能否成为新标准？
Lancet. 2023 Oct 7;402(10409):1217-1218. doi: 10.1016/S0140-6736(23)01521-0. Epub 2023 Sep 11.
9
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.一项关于新辅助脂质体伊立替康联合 5-FU 和奥沙利铂（NALIRIFOX）治疗胰腺腺癌的 II 期研究。
Future Oncol. 2023 Sep;19(27):1841-1851. doi: 10.2217/fon-2023-0256. Epub 2023 Sep 27.
10
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?纳立妥昔用于转移性胰腺癌的一线治疗：FOLFIRINOX方案最终会被取代吗？
Future Oncol. 2023 Mar;19(9):617-620. doi: 10.2217/fon-2023-0088. Epub 2023 May 2.
本文引用的文献
1
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.脂质体伊立替康在转移性胰腺癌一线治疗中的整合：试着不要去想白熊。
Ther Adv Med Oncol. 2024 Apr 4;16:17588359241234487. doi: 10.1177/17588359241234487. eCollection 2024.
2
The impacts of exposure to risk factors during youth on the increasing global trend of early-onset pancreatic cancer.青少年时期接触风险因素对全球早发性胰腺癌发病率不断上升的影响。
Public Health. 2024 Apr;229:65-72. doi: 10.1016/j.puhe.2023.11.006. Epub 2024 Feb 24.
3
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.NALIRIFOX、FOLFIRINOX 和吉西他滨联合 Nab-紫杉醇作为转移性胰腺癌一线化疗：系统评价和荟萃分析。
JAMA Netw Open. 2024 Jan 2;7(1):e2350756. doi: 10.1001/jamanetworkopen.2023.50756.
4
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial.可切除胰腺导管腺癌患者围手术期 NALIRIFOX：开放性、多中心、Ⅱ期 nITRO 试验。
Eur J Cancer. 2024 Jan;196:113430. doi: 10.1016/j.ejca.2023.113430. Epub 2023 Nov 11.
5
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.一项关于新辅助脂质体伊立替康联合 5-FU 和奥沙利铂（NALIRIFOX）治疗胰腺腺癌的 II 期研究。
Future Oncol. 2023 Sep;19(27):1841-1851. doi: 10.2217/fon-2023-0256. Epub 2023 Sep 27.
6
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌（NAPOLI 3）：一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
7
Overview of Pancreatic Cancer Epidemiology in Europe and Recommendations for Screening in High-Risk Populations.欧洲胰腺癌流行病学概述及高危人群筛查建议
Cancers (Basel). 2023 Jul 15;15(14):3634. doi: 10.3390/cancers15143634.
8
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.一线治疗胰腺导管腺癌的脂质体伊立替康联合奥沙利铂、5-氟尿嘧啶和亚叶酸（NALIRIFOX）：一项 I/II 期研究。
Eur J Cancer. 2021 Jul;151:14-24. doi: 10.1016/j.ejca.2021.03.028. Epub 2021 May 4.
9
Malignant epithelial/exocrine tumors of the pancreas.胰腺的恶性上皮/外分泌肿瘤。
Pathologica. 2020 Sep;112(3):210-226. doi: 10.32074/1591-951X-167.
10
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.接受脂质体伊立替康联合氟尿嘧啶和亚叶酸治疗的转移性胰腺癌患者的生活质量。
Eur J Cancer. 2019 Jan;106:24-33. doi: 10.1016/j.ejca.2018.09.029. Epub 2018 Nov 17.
Zotero 插件